CHATEAL
CHATEAL — levonorgestrel and ethinyl estradiol
Afaxys Pharma, LLC
Chateal®
(Levonorgestrel and Ethinyl Estradiol Tablets, USP 0.15 mg/0.03 mg)
Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
DESCRIPTION
21 white to off-white levonorgestrel and ethinyl estradiol tablets , each containing 0.15 mg of levonorgestrel, (d(-)-13 beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one), a totally synthetic progestogen, and 0.03 mg of ethinyl estradiol, (19-nor-17α -pregna-1,3,5 (10)-trien-20-yne-3,17-diol), and 7 green inert tablets. The inactive ingredients for white to off-white active tablets are Lactose monohydrate, Polacrilin Potassium, Magnesium Stearate. The inactive ingredients for green inert tablets are Lactose monohydrate, Polacrilin Potassium, Magnesium Stearate, yellow oxide of iron and FD&C Blue No.1 Aluminium lake.
CLINICAL PHARMACOLOGY
Combination oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
INDICATIONS AND USAGE
Oral contraceptives are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.
Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and the IUD, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates.
| NA — not available | ||
| a Depending on method (calendar, ovulation, symptothermal, post-ovulation) | ||
| Adapted from Hatcher RA et al, Contraceptive Technology : 17th Revised Edition . | ||
| NY, NY: Ardent Media, Inc., 1998. | ||
| Method | Perfect Use | Typical Use |
| Levonorgestrel implants | 0.05 | 0.05 |
| Male sterilization | 0.1 | 0.15 |
| Female sterilization | 0.5 | 0.5 |
| Depo-Provera® (injectable progestogen) | 0.3 | 0.3 |
| Oral contraceptives | 5 | |
| Combined | 0.1 | NA |
| Progestin only | 0.5 | NA |
| IUD | ||
| Progesterone | 1.5 | 2.0 |
| Copper T 380A | 0.6 | 0.8 |
| Condom (male) without spermicide | 3 | 14 |
| (Female) without spermicide | 5 | 21 |
| Cervical cap | ||
| Nulliparous women | 9 | 20 |
| Parous women | 26 | 40 |
| Vaginal sponge | ||
| Nulliparous women | 9 | 20 |
| Parous women | 20 | 40 |
| Diaphragm with spermicidal cream or jelly | 6 | 20 |
| Spermicides alone (foam, creams, jellies, and vaginal suppositories) | 6 | 26 |
| Periodic abstinence (all methods) | 1 to 9a | 25 |
| Withdrawal | 4 | 19 |
| No contraception (planned pregnancy) | 85 | 85 |
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.